Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
36.46
0.00 (0.00%)
At close: Nov 13, 2026, 4:00 PM EST
36.46
-0.01 (-0.01%)
After-hours: Nov 13, 2026, 7:30 PM EST
Pacira BioSciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 743.3 | 726.41 | 700.97 | 674.98 | 666.82 | 541.53 | |
Revenue Growth | 3.70% | 3.63% | 3.85% | 1.22% | 23.14% | 26.04% |
Cost of Revenue | 164.61 | 149.75 | 170.43 | 184.67 | 199.3 | 140.26 |
Gross Profit | 578.69 | 576.66 | 530.54 | 490.31 | 467.53 | 401.28 |
Selling, General & Admin | 371.2 | 368.76 | 294.1 | 269.44 | 254.52 | 199.35 |
Research & Development | 122.45 | 117.31 | 81.58 | 76.26 | 84.8 | 55.55 |
Amortization of Goodwill & Intangibles | 55.32 | 57.29 | 57.29 | 57.29 | 57.29 | 13.55 |
Other Operating Expenses | - | - | - | - | - | 42.91 |
Operating Expenses | 548.97 | 543.36 | 432.96 | 402.99 | 396.6 | 311.35 |
Operating Income | 29.72 | 33.3 | 97.57 | 87.32 | 70.93 | 89.92 |
Interest Expense | -14.1 | -17.45 | -16.57 | -20.31 | -39.98 | -31.75 |
Interest & Investment Income | 8.66 | 22.73 | 19.69 | 11.44 | 4.54 | 0.9 |
Other Non Operating Income (Expenses) | -0.03 | -10.81 | -0.37 | -0.19 | -1.29 | -0.07 |
EBT Excluding Unusual Items | 24.26 | 27.78 | 100.32 | 78.28 | 34.21 | 59 |
Merger & Restructuring Charges | -1.5 | -6.57 | -9.99 | -3.07 | -11.25 | - |
Impairment of Goodwill | - | - | -163.24 | - | - | - |
Gain (Loss) on Sale of Investments | - | 4.19 | - | - | -10 | -2.6 |
Asset Writedown | - | -25.87 | - | - | -26.13 | - |
Legal Settlements | - | 16.15 | - | - | - | - |
Other Unusual Items | 14.2 | 1.19 | 9.81 | -13.5 | 26.48 | - |
Pretax Income | 36.94 | 16.87 | -63.11 | 61.7 | 13.3 | 56.4 |
Income Tax Expense | -0.79 | 9.84 | 36.45 | 19.75 | -2.61 | 14.42 |
Net Income | 37.73 | 7.03 | -99.56 | 41.96 | 15.91 | 41.98 |
Net Income to Common | 37.73 | 7.03 | -99.56 | 41.96 | 15.91 | 41.98 |
Net Income Growth | 75.98% | - | - | 163.72% | -62.10% | -71.15% |
Shares Outstanding (Basic) | 41 | 45 | 46 | 46 | 46 | 44 |
Shares Outstanding (Diluted) | 42 | 45 | 46 | 52 | 47 | 46 |
Shares Change | -8.52% | -2.60% | -11.03% | 11.69% | 1.99% | 4.46% |
EPS (Basic) | 0.93 | 0.16 | -2.15 | 0.91 | 0.35 | 0.95 |
EPS (Diluted) | 0.91 | 0.16 | -2.15 | 0.89 | 0.34 | 0.92 |
EPS Growth | 93.67% | - | - | 160.68% | -63.04% | -72.37% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 169 | 136.66 | 178.75 | 139.49 | 115.2 | 79.85 |
Free Cash Flow Per Share | 4.06 | 3.03 | 3.87 | 2.68 | 2.48 | 1.75 |
Gross Margin | 77.85% | 79.38% | 75.69% | 72.64% | 70.11% | 74.10% |
Operating Margin | 4.00% | 4.58% | 13.92% | 12.94% | 10.64% | 16.61% |
Profit Margin | 5.08% | 0.97% | -14.20% | 6.22% | 2.39% | 7.75% |
Free Cash Flow Margin | 22.74% | 18.81% | 25.50% | 20.67% | 17.28% | 14.74% |
EBITDA | 118.37 | 124.33 | 176.36 | 162.9 | 151.93 | 118.47 |
EBITDA Margin | 15.93% | 17.11% | 25.16% | 24.13% | 22.78% | 21.88% |
D&A For EBITDA | 88.65 | 91.02 | 78.79 | 75.57 | 81 | 28.55 |
EBIT | 29.72 | 33.3 | 97.57 | 87.32 | 70.93 | 89.92 |
EBIT Margin | 4.00% | 4.58% | 13.92% | 12.94% | 10.64% | 16.61% |
Effective Tax Rate | - | 58.31% | - | 32.00% | - | 25.57% |
Revenue as Reported | 743.3 | 726.41 | 700.97 | 674.98 | 666.82 | 541.53 |